Title
Stimulating therapy for obstructive sleep apnoea

Permalink
https://escholarship.org/uc/item/09q0t1hh

Journal
THORAX, 71(10)

ISSN
0040-6376

Authors
Jr, SPJ
Malhotra, A

Publication Date
2016-10-01

DOI
10.1136/thoraxjnl-2016-209077

Peer reviewed
The proof of your manuscript appears on the following page(s).

It is the responsibility of the corresponding author to check against the original manuscript and approve or amend these proofs.

Please read the proofs carefully, checking for accuracy, verifying the reference order and checking figures and tables. When reviewing your page proof please keep in mind that a professional copyeditor edited your manuscript to comply with the style requirements of the journal.

**This is not an opportunity to alter, amend or revise your paper; it is intended to be for correction purposes only.** The journal reserves the right to charge for excessive author alterations or for changes requested after the proofing stage has concluded.

During the preparation of your manuscript for publication, the questions listed below have arisen (the query number can also be found in the gutter close to the text it refers to). Please attend to these matters and return the answers to these questions when you return your corrections.

**Please note, we will not be able to proceed with your article if these queries have not been addressed.**

* A second proof is not normally provided.

### Note Reference | Note
---|---
N1 | **IMPORTANT:** Corrections at this stage should be limited to those that are essential. Extensive corrections will delay the time to publication and may also have to be approved by the Editor. **Alterations cannot be made after the article has published online.**
N2 | Author SURNAMES (family names) have been highlighted - please check that these are correct. Please check all names are spelt correctly, and that affiliations and correspondence details are accurate.
N3 | Your article should display in PubMed within 1 week of Online First publication. If you have paid for Open Access, your article will be sent to PubMed Central upon issue publication.

### Query Reference | Query
---|---
Q1 | Please check placement of text.

If you are happy with the proof as it stands, please email to confirm this. Minor changes that do not require a copy of the proof can be sent by email (please be as specific as possible).

**Email:** production.thorax@bmj.com

If you have any changes that cannot be described easily in an email, please mark them clearly on the proof using the annotation tools and email this by reply to the eProof email.
We will keep a copy of any correspondence from you related to the author proof for six months. After six months, correspondence will be deleted.

Please respond within 48 hours
Stimulating therapy for obstructive sleep apnoea

Patrick J Strollo Jr, Atul Malhotra

The burden of obstructive sleep apnoea (OSA) is increasing due to the worldwide obesity epidemic and the ageing of the population. The treatment of OSA is unsatisfactory for some patients since tolerance of the gold standard treatment positive airway pressure (PAP) is quite variable. Among patients who tolerate PAP results are excellent; however, effectiveness is limited by variable adherence.

Improvements in our understanding of OSA pathogenesis have led to a concept that the mechanism (endotype) underlying OSA is highly variable across individuals such that some patients have primarily an upper airway anatomical problem, whereas others have dysfunction in upper airway dilator muscles, some have unstable control of breathing and some may have combinations of abnormalities.

This realisation has led to the concept of personalised medicine in OSA such that therapies could theoretically be targeted to the mechanism underlying apnoea rather than using a ‘one-size-fits-all’ approach.

Efforts to improve treatment are ongoing by developing new therapeutic approaches (eg, hypoglossal nerve stimulation). This approach augments the neural output to upper airway dilator muscles as opposed to ‘pneumatically splitting’ the airway open in the case of PAP therapy or mechanically enlarging the airway as is done with oral appliance therapy.

Strollo et al. have demonstrated that phasic unilateral electrical stimulation of the hypoglossal nerve is safe and effective in carefully selected participants with moderate-to-severe OSA, who could not accept or adhere to PAP. The durability of the treatment effect has been sustained up to 36 months.

The report by Pengo in this issue has approached upper airway stimulation in a different manner. These investigators examined the impact of bilateral submental transcutaneous electrical stimulation (TCES) of the upper airway in patients with OSA. This work is an extension of the feasibility study reported by this group in 2011.

The authors should be commended for a number of strengths related to this study —rigorous design (randomised sham control), careful measurement of sleep and particularly sleep disruption as well as the assessment of participant symptoms related to TCES. The caveats of this report relate to the fact that the primary outcome (4% oxygen desaturation index) was examined after one night of stimulation in the sleep laboratory; the treatment effect was modest and the active intervention (tonic stimulation) did not impact the apnoea-hypopnoea index in rapid eye movement sleep.

A number of questions remain that merit comment: (1) What muscles/muscle groups are being stimulated? The upper airway has 23 different pairs of muscles with considerable complexity (phasic vs tonic, protruders vs retractors, etc); thus, further efforts will be required regarding precise mechanisms of surface stimulation. (2) What patient endotype responds best to TCES? Considerable work is ongoing suggesting only a subset of patients with OSA have a major issue with upper airway dilator muscle function. Thus, one might predict that efforts to augment hypoglossal motor output may be more effective for some patients than for others with OSA depending on underlying mechanism. (3) Is bilateral stimulation and opposition to unilateral stimulation the better approach? Clinical trials will be required to compare these approaches, although physiological studies (eg, comparing unilateral vs bilateral stimulation on pharyngeal mechanics) would also be valuable in addressing this question. (4) Can one night of treatment with this device refine selection for implantable systems? Such an approach might allow clinicians to determine a priori which patients should undergo the risk and expense of an implantable nerve stimulator. (5) If TCES is used as a stand-alone treatment, what is the long-term impact on sleep, sleep disorders breathing, patient symptoms (ie, snoring, sleepiness and quality of life), patient acceptance/adherence and long-term cardiovascular/metabolic risk?

While the overall response to TCES was modest, it is conceivable that refining the patient selection by identifying endotypes that might respond to this therapy would strengthen the value of this approach. Future work could possibly incorporate drug-induced sedation endoscopy to examine favourable patterns of airway collapse or assessment of the physiologic signature of airflow.

Such approaches could help to identify those patients with dysfunction in upper airway dilator muscle control who may be responsive to stimulation approaches. On the other hand, patients with OSA with an issue primarily of unstable ventilatory control or low arousal threshold may be predicted to fail treatment targeted just at upper airway dilator muscles.

We applaud the authors for moving forward our understanding of electrical stimulation of the upper airway and fueling further research in this area.

Competing interests: None declared.

Provenance and peer review: Commissioned; externally peer reviewed.

PJS is a co-investigator on R01 DK096028-02, R01 HL120354-01A1, 1UH2HL125103-01, U101HL128954 and 5UL1TR000005-09. He has research grants from Philips Respironics, ResMed, Inspire Medical Systems and Jazz Pharmaceuticals. He has received consulting fees from Inspire Medical Systems, ResMed, Emmi Solutions, Jazz Pharmaceuticals, Itamar Medical and the National Football League.

AM is PI on NIH R01 HL085188 and K24 HL132105 and co-investigator on R21 HL121794, R01 HL19201 and R01 HL018283. As an Officer of the American Thoracic Society, AM has relinquished all outside personal income since 2012. ResMed provided a philanthropic donation to the University of California, San Diego in support of a sleep centre, which AM’s division runs.

To cite: Strollo PJ, Malhotra A. Thorax Published Online First: [please include Day Month Year] doi:10.1136/thoraxjnl-2016-209077

REFERENCES


